Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

#2864

Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.

Aim(s): The aim of this study is to evaluate the efficacy and the safety of Irinotecan (IRI)-based chemotherapy in extrapulmonary NECs.

Materials and methods: Patients with a diagnosis of NEC treated at University Hospital of Modena with an IRI-based regimen (FOLFIRI or CAPIRI) after progression to a first-line platinum-based therapy were analyzed. Objective responses were assessed according to RECIST criteria. Time-to-progression (TTP) and overall survival (OS) were calculated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,

Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,